



## Scientific Letter

## Brain Calcifications and Primary Hyperparathyroidism<sup>☆</sup>



### Calcificaciones cerebrales e hiperparatiroidismo primario


Bilateral cerebral calcifications that affect the basal ganglia are detected in 0.68%–0.93% of cranial computed tomography (CT) scans.<sup>1,2</sup> They have been reported in asymptomatic patients and in a variety of neurological conditions. Cerebral calcifications are classified into 3 groups: physiological, idiopathic (including Fahr disease) and secondary to calcium metabolism alterations.<sup>3</sup> The most common causes of these calcifications with a striatum-pallidus-dentate distribution are the calcium-phosphorus metabolism disorders: hypoparathyroidism, pseudohypoparathyroidism, pseudo-pseudohypoparathyroidism and hyperparathyroidism. However, all chronic hypocalcaemia states, such as renal failure (the most frequent), vitamin D deficiency, hypomagnesaemia, pancreatitis and hypoparathyroidism, can be associated with intracranial calcifications.<sup>4</sup> The association of basal ganglia calcifications and primary hyperparathyroidism is exceptional. We present a recent case and review data from the literature.

The patient is a 49-year-old woman who had been admitted due to an episode of partial left visual impairment and affected sensorimotor function of the left arm, of undetermined aetiology, which completely resolved spontaneously. She reported no medical history of interest, no family history of Fahr disease or Fahr syndrome, and no calcium-phosphorus metabolism diseases. She had had no previous fractures. Cranial CT study observed coarse calcifications in the basal and periventricular ganglia, as well as the bilateral frontal lobe and convexity (Fig. 1). The study was completed with a magnetic resonance imaging (MRI) scan of the brain, which revealed symmetrical calcifications in the basal ganglia, dentate nucleus of the cerebellum and in the union of the grey and white matter, which corresponded with the calcifications seen on CT scan.

The lab work showed: calcium 10.0 mg/dL, phosphorus 2.8 mg/dL, calcium × phosphorus product 28.0, total protein 65.4 g/L, 24 h calciuria 365 mg/vol (normal: 110–250), PTH 172.7 pg/mL (normal: 11–67), and calcifediol 11 ng/mL. Other

inflammatory, infectious and metabolic conditions were ruled out.

The images from the parathyroid scintigraphy and ultrasound were compatible with the presence of a left upper parathyroid adenoma. Bone densitometry showed the spinal column T-score of +0.46 and left hip T-score of –0.19. The diagnosis of primary hyperparathyroidism probably secondary



**Fig. 1 – Axial CT: calcifications observed in bilateral frontal and periventricular basal ganglia.**

<sup>☆</sup> Please cite this article as: de la Plaza Llamas R, Ramia Ángel JM, Arteaga Peralta V, Hernández Cristóbal J, López Marcano AJ. Calcificaciones cerebrales e hiperparatiroidismo primario. Cir Esp. 2016;94:e5-e7.

**Table 1 – Characteristics of the Patients With Bilateral Cerebral Calcifications and Primary Hyperparathyroidism.**

Author, year	Age/Sex	Symptoms	Radiological tests	Location of calcifications	Calcaemia/ Phosphorus/ PTH	Parathyroidectomy	Evolution
Kisner et al., <sup>5</sup> 1956	58/M	Parkinsonian symptoms, progressive emotional and intellectual decline, convulsions	Radiography	BCC in caudate nucleus and frontal lobes	12.4 mg/dL 3 mg/dL	Not considered; right cystic intrathyroid adenoma	Death 33 months after diagnosis due to myocardial infarction (necropsy)
Margolin et al., <sup>6</sup> 1980	64/F	Parkinsonian symptoms, gait apraxia, frontal lobe dysfunction, normal mental state	Radiography, CT	BCC in cerebellum, thalamus, dentate nucleus, do, globus pallidus, cerebellum, frontal and parietal lobes	11.3 mg/dL 3 mg/dL 130 pg/mL	No, rejected by patient	Unknown
Orwoll et al., <sup>7</sup> 1981	84/F	Parkinsonian symptoms, gait apraxia, memory loss, frontal lobe dysfunction	Radiography, CT	BCC in basal ganglia, thalamus and frontal lobes	10.6–11.4 mg/dL 2.6 mg/dL 157 pg/mL	Upper left 2.5 cm × 1.5 cm × 0.9 cm	Neurological symptoms improved, sensory and gait involvement normalised, calcifications disappeared
El Maghraoui et al., <sup>8</sup> 1995	62/F	Extrapyramidal rigidity, altered behaviour, epileptic crises	CT	BCC in pallidum	12.8 mg/dL 5.4 mg/dL	Lower right	Seizures disappeared, behaviour disorder improved, extrapyramidal rigidity persisted
De la Plaza et al., 2015	49/F	Partial left visual disorder and sensorimotor dysfunction affected LUL	CT, MRI	BCC in basal ganglia, dentate nuclei of the cerebellum, frontal lobes and convexity	10.6 mg/dL 2.8 mg/dL 173 pg/mL	Upper left	Absence of neurological symptoms, radiology tests unchanged

BCC: bilateral cerebral calcifications; CT: computed tomography; F: female; LUL: left upper limb; PTH: parathyroid hormone; M: male; MRI: magnetic resonance imaging.

to left upper adenoma was established. Even though it did not meet criteria of parathyroidectomy established in the *Third* and more recently the *Fourth International Workshop on the Management of Asymptomatic Primary Hyperthyroidism*,<sup>9,10</sup> but given the possibility of progression of the cerebral calcium deposit, we opted for surgical intervention.

Nineteen months after the neurological episode, the patient underwent major ambulatory surgery involving minimally invasive parathyroidectomy with intraoperative monitoring, meeting the criteria for a biochemical cure. The pathology result was a 0.52 g parathyroid adenoma. During follow-up, 4 months after the intervention, the patient has had no new neurological alterations, and the follow-up lab work showed calcium 9.0 mg/dL, phosphorus 3.3 mg/dL, calcium × phosphorus product 29.7, total protein 65.7 g/L, albumin 38.7 g/L, 24 h calciuria 266 mg/vol, PTH 28.9 pg/mL and calcifediol 40 ng/mL. The cerebral CT showed no changes compared to the original scan.

To determine the frequency of the association of primary hyperparathyroidism and cerebral calcifications, we performed a PubMed search without limits, last updated on 1 May 2015, and

the following strategy: ([Cerebral Calcifications] OR [Brain Calcification] OR [Basal Ganglia Calcifications] OR [Central Nervous System Calcifications] OR [Intracranial Calcifications] AND [Hyperparathyroidism]). The search obtained 35 results. The articles and related bibliographic references were reviewed.

The possible causes of cerebral calcifications are metastatic deposits secondary to a local alteration of the blood-brain barrier or a neuronal calcium metabolism disorder.

In the review of the literature, only 4 patients have been reported,<sup>5–8</sup> 2 of which were simultaneously included in 2 articles,<sup>6,7</sup> who presented primary hyperparathyroidism and cerebral calcifications. The characteristics of the 4 patients described in the literature are summarised in [Table 1](#).

All the patients presented Parkinsonian symptoms and 2 of them had convulsive crises. It should be mentioned that 2 patients were not operated on. In the first case,<sup>5</sup> surgery was not proposed to the patient, and the diagnosis of adenoma was established during necropsy. There was a progressive neurological decline until the patient died of a myocardial infarction 33 months after diagnosis. The evolution of the second patient, who rejected the procedure, is unknown.<sup>6</sup>

The other 2 patients who underwent parathyroidectomy experienced improved neurological syndrome, including the disappearance of seizures, the behaviour alteration in one of them,<sup>8</sup> and sensory and gait alterations in the other. Calcifications practically disappeared from their CT scans.<sup>7</sup> It should also be mentioned that the patient described in the article by El Maghraoui et al.<sup>8</sup> with the diagnosis of parathyroid adenoma presented phosphates of 5.4 mg/dL, which is hardly compatible with primary hyperparathyroidism.

The patient that we report in this article is the fifth case in the literature with associated bilateral basal ganglia calcifications and primary hyperparathyroidism. Although the coincidence of the different 2 entities cannot be ruled out, in the 2 previous cases published that had undergone resection of the adenoma, improvements were seen in the neurological symptoms in one and, in the other, the calcifications virtually disappeared. In our patient, 46 months after parathyroidectomy and 65 after the neurological symptoms and CT diagnosis, the basal ganglia calcifications have not progressed, nor have there been any further neurological symptoms. We do not know if the patient would have developed a more severe neurological condition if we had not performed parathyroidectomy, as was the case in the other 4 patients mentioned in our review. We therefore believe that parathyroidectomy is indicated in this association.

## REFERENCES

1. Sanchette P, Venkataraman S, Mohan C, Shetty DD, Lyengar G. Basal ganglia calcification. *J Assoc Physicians India*. 1999;47:507-9.
2. Tedrus GM, Fonseca LC, Nogueira E Jr. Basal ganglia calcification on computed tomography: clinical characteristics in 25 patients. *Arq Neuropsiquiatr*. 2006;64:104-7.
3. Lira D, Custodio N, Montesinos R, Torres H. Calcificaciones cerebrales extensas y corea, en hipoparatiroidismo probablemente postquirúrgico. *An Fac Med*. 2009;70:119-22.
4. Bonazza, La Morgia C, Martinelli P, Capellari S. Strio-pallido-dentate calcinosis: diagnostic approach in adult patients. *Neurol Sci*. 2011;32:537-45.
5. Kisner P, Knuth WP. Symmetrical cerebral calcification associated with parathyroid adenoma. *J Am Med Assoc*. 1956;162:462-4.
6. Margolin D, Hammerstad J, Orwoll E, McClung M, Calhoun D. Intracranial calcification in hyperparathyroidism associated with gait apraxia and parkinsonism. *Neurology*. 1980;30:1005-7.
7. Orwoll E, Margolin D, Hammerstad J, Calhoun D, McClung M. Hyperparathyroidism and intracerebral calcification. *Miner Electrolyte Metab*. 1981;5:273-9.
8. El Maghraoui A, Birouk N, Zaim A, Slassi I, Yahyaoui M, Chkili T. Fahr syndrome and dysparathyroidism. 3 cases. *Presse Med*. 1995;24:1301-4 [article in French].
9. Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. *J Clin Endocrinol Metab*. 2009;94:335-9.
10. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. *J Clin Endocrinol Metab*. 2014;99:3561-9.

Roberto de la Plaza Llamas<sup>a,\*</sup>, José Manuel Ramia Ángel<sup>a</sup>, Vladimir Arteaga Peralta<sup>a</sup>, Jaime Hernández Cristóbal<sup>b</sup>, Aylhin Joana López Marcano<sup>a</sup>

<sup>a</sup>Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario de Guadalajara, Guadalajara, Spain

<sup>b</sup>Sección de Neurología, Hospital Universitario de Guadalajara, Guadalajara, Spain

\*Corresponding author.

E-mail address: rdplazal@sescam.jccm.es (R. de la Plaza Llamas).

2173-5077/

© 2015 Published by Elsevier España, S.L.U. on behalf of AEC.